Stay informed on the latest clinical trials and medical surveys with up-to-date information on new studies and emerging research.
SIRIUS – LN (NCT05126277)
A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants With Active Lupus Nephritis (SIRIUS-LN)
This trial will evaluate the efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or ianalumab given every 12 weeks (q12w) compared to placebo, in combination with Standard of Care (SoC), in adult participants with active LN (ISN/RPS class III, IV active glomerulonephritis with or without co-existing class V features, or pure class V membranous), using the 2003 International Society for Nephrology (ISN)/Renal Pathology Society (RPS) criteria).
You may qualify if the following eligibility criteria are met:
• 18 years of age and older
• Have a confirmed clinical diagnosis of SLE
• Have a positive anti-nuclear antibody (ANA) test result
• Active LN at screening, as defined by meeting the 3 following criteria:
• Renal biopsy within 6 months prior to screening period indicating ISN/RPS class III or IV active glomerulonephritis with or without co-existing class V features, or pure class V membranous LN.
• UPCR ≥ 1.0 g/g on 24h urine collection at Screening
• eGFR ≥ 25mL/min/1.73 m2
• plus more details at the link below
Toronto Western Hospital is part of the recruitment for this study.
Learn more here: https://clinicaltrials.gov/study/NCT05126277
SIRIUS – SLE 1 (NCT05126277)
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE). A randomized, double-blind, parallel group, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of two regimens of ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 1)
You may qualify if the following eligibility criteria are met:
• 12 years of age and older
• Diagnosed with SLE
• plus more details at the link below
Hamilton Health Sciences and Toronto Western are part of the recruitment for this study.
Learn more here: https://www.novartis.com/clinicaltrials/study/nct05639114
SELECT-SLE (NCT05843643)
Toronto Western Hospital is part of the recruitment for this study.
Learn more here: https://clinicaltrials.gov/study/NCT05843643
Please Note: This study is open to participants from around the world, and eligible individuals globally are encouraged to take part.
The deadline for the study is December 2025
HAVE YOU EXPERIENCED MULTIPLE CHRONIC HEALTH CONDITIONS DURING PREGNANCY?You may be eligible to participate in the Pregnancy and People with Multiple Chronic Health Conditions study if you:
- Are 18 years or older
- Have at least two chronic health conditions or disabilities. This can include: physical and mental health conditions, and/or disabilities.
- Have had a pregnancy in the last ten years.
- Live in Canada.
Do you live with autoimmune arthritis and have a child under 6 years old? Share your experiences to help develop supports for new parents living with inflammatory arthritis. You will be provided with a gift card for your time.
You must be a Canadian resident, have an autoimmune rheumatic disease (ARD), and at least one child the age of 5 or under. Participate here.
This survey aim to assess the knowledge of people living with lupus about their own disease. Several investigators from different centres and countries are involved in this effort led by Dr Arnaud and his team.
The Systemic Lupus Assessment score for Essential Knowledge (SLAKE) is an online tool designed to help patients living with lupus to take control and better understand this complex disease.
- There are 44 questions taken at random from a pool of 400 questions which will test how well you understand 11 different lupus areas.
- The typical completion time for SLAKE is less than 5 minutes
The primary aim of SLAKE is to allow individuals living with lupus to test their knowledge across 11 key domains, after which they can access videos designed to reinforce their understanding in areas that may need further attention (the videos are being planned) Participate in the survey here.
It is recommended that the patient enter the name of the centre or clinic they are being followed at in the dedicated field (‘centre’) during the survey.
PARTICIPANTS WANTED FOR ONLINE RESEARCH STUDY
Topic: Pain Mapping & Psychosocial Predictors of Depressive Symptoms in Individuals with Lupus
- The Pain Lab in the Department of Psychology at Queen’s University is looking for volunteers to complete some questions regarding their pain, mood, social support, and beliefs related to pain.
- Must be 18 years of age or older
- Must be able to speak, read, and write in English
- Must be diagnosed with Lupus. Please note that there will be no incentives for participating.
To access the study, visit the study here
If you have any questions, email at painlab@queensu.ca.
This study has received ethical approval by the Queen’s University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board Version